Importantly, the anti-cancer agent CX5461, which is currently in phase I/II trials (NCT02719977) and therapeutically targets rDNA transcription23, inhibits resveratrol induced expression of the PGC-1α target gene complex V (Figure S6). This evidence concerns the gene PPARGC1A and cancer.